Anti-ROR1 CAR T-cell therapy(Oncternal Therapeutics)

N/A

Report date: 2024/05/30 17:46:52

Base Information

Drug NameAnti-ROR1 CAR T-cell therapy(Oncternal Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1T lymphocyte replacements

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOncternal Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesOncternal Therapeutics Inc Lentigen Technology Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A